1. Home
  2. EDIT vs EVC Comparison

EDIT vs EVC Comparison

Compare EDIT & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDIT
  • EVC
  • Stock Information
  • Founded
  • EDIT 2013
  • EVC 1996
  • Country
  • EDIT United States
  • EVC United States
  • Employees
  • EDIT N/A
  • EVC N/A
  • Industry
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • EVC Broadcasting
  • Sector
  • EDIT Health Care
  • EVC Industrials
  • Exchange
  • EDIT Nasdaq
  • EVC Nasdaq
  • Market Cap
  • EDIT 269.8M
  • EVC 226.5M
  • IPO Year
  • EDIT 2016
  • EVC 2000
  • Fundamental
  • Price
  • EDIT $3.92
  • EVC $2.27
  • Analyst Decision
  • EDIT Buy
  • EVC
  • Analyst Count
  • EDIT 11
  • EVC 0
  • Target Price
  • EDIT $4.56
  • EVC N/A
  • AVG Volume (30 Days)
  • EDIT 2.7M
  • EVC 192.2K
  • Earning Date
  • EDIT 11-03-2025
  • EVC 11-05-2025
  • Dividend Yield
  • EDIT N/A
  • EVC 8.81%
  • EPS Growth
  • EDIT N/A
  • EVC N/A
  • EPS
  • EDIT N/A
  • EVC N/A
  • Revenue
  • EDIT $38,901,000.00
  • EVC $396,704,000.00
  • Revenue This Year
  • EDIT N/A
  • EVC $64.06
  • Revenue Next Year
  • EDIT N/A
  • EVC N/A
  • P/E Ratio
  • EDIT N/A
  • EVC N/A
  • Revenue Growth
  • EDIT N/A
  • EVC 25.34
  • 52 Week Low
  • EDIT $0.91
  • EVC $1.58
  • 52 Week High
  • EDIT $4.05
  • EVC $2.73
  • Technical
  • Relative Strength Index (RSI)
  • EDIT 73.38
  • EVC 40.12
  • Support Level
  • EDIT $3.01
  • EVC $2.23
  • Resistance Level
  • EDIT $3.58
  • EVC $2.62
  • Average True Range (ATR)
  • EDIT 0.30
  • EVC 0.07
  • MACD
  • EDIT 0.10
  • EVC -0.02
  • Stochastic Oscillator
  • EDIT 91.42
  • EVC 12.90

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

About EVC Entravision Communications Corporation

Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.

Share on Social Networks: